The First Prototypes Were Developed in My Hobby Workshop
The VitrofluidiX story begins in a typical startup garage setting. Given my unconventional educational path, it was frequently challenging to persuade people of our capabilities and vision.
VitrofluidiX, founded by David Günter and Carlotta Altringer in Cologne, specializes in Organ-on-a-Chip technology. Their flagship product, VitroFlow, replicates human body conditions, enabling human cells to function as they would in their original tissue.
David's background is distinctive: he began studying chemistry at 14, switched to biology at 15, and was conducting microfluidic research by 16. The startup addresses a significant gap in medical research by providing unified systems for controlling microfluidic chips.
Their technology enables drug development without animal testing, personalized medication assessment, and more accurate results at reduced costs. The business model encompasses the VitroFlow system, partnerships with scientific organizations, and consumable products. Despite initial difficulties convincing investors due to their youth, the team secured funding.
Current objectives include obtaining CE certification, completing seed funding of €2.3 million, and developing new product versions. The six-member team possesses expertise across biology, engineering, and business development.
This article has been summarized and translated using AI to help you practice reading and comprehension. While we strive for accuracy, some nuances may be lost in translation.